Get Free Trial
News & Analysis
On The Fly
About The Fly
Instant updates and real-time market news.
Bellicum Pharmaceuticals reports Q2 EPS (60c), consensus (55c)
Reports Q2 revenue $362,000, consensus $70K.
Bellicum clinical hold should lift soon, says Jefferies
Jefferies analyst Biren Amin says Bellicum Pharmaceuticals last night provided an update of its leading prgm BPX-501 with an "encouraging" survival rate at one year in pediatric acute myeloid leukemia patients. For BPX-601, management reported CART cell expansion in one pancreatic cancer patient following rimiducid administration, providing first patient validation of the company's activation switch, Amin tells investors in a post-earnings research note. The analyst notes Bellicum has also responded to FDA including proposed protocol changes. Amin believes the clinical hold should lift soon and keeps a Buy rating on Bellicum Pharmaceuticals with a $16 price target.
Bellicum Pharmaceuticals upgraded to Outperform at Wells Fargo
Wells Fargo upgrades Bellicum to Outperform on lifting of clinical hold
Wells Fargo analyst Jim Birchenough last night upgraded Bellicum Pharmaceuticals to Outperform from Market Perform and raised his price target for the shares to $23 from $6. The shares in premarket trading are up 27% to $8.70 following news that the FDA lifted the clinical hold on studies of BPX-501 in the U.S. Rapid resolution of the clinical hold "substantially de-risks the investment," Birchenough tells investors in a research note. He believes Bellicum's platform for controllable cell therapies is well positioned for therapeutic oncology indications.
Bellicum price target raised to $18 from $10 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Bellicum Pharmaceuticals to $18 following the announcement of the FDA's lift of its U.S. clinical hold for BPX-501. The analyst now has increased confidence across the BPX-501 platform. He reiterates an Overweight rating on the shares.
TODAY'S FREE FLY STORIES